The New York Times has an article this morning indicating that the maker of the drug Heparin has instituted a recall. In the article, it is revealed that the Food and Drug Administration has admitted that it failed to follow its own guidelines by failing to inspect the Chinese plant where a critical ingredient of heparin is made from pig intestines. This is an interesting development given that the Supreme Court of the United States ruled last week that approval by the FDA of a medical device precludes injured plaintiffs from suing manufacturers under state law. Read more about that case here. Hopefully, the Heparin case will prompt our legislators to turn a critical eye toward the FDA and its oversight and approval process. It appears that this may already be happening. According to the FDA itself, it is almost incapable of carrying out it's wide ranging mission. Governmentexecutive.com reports that a soon to be released report of the FDA finds that "The Food and Drug Administration faces shortfalls in staffing and information technology, which have resulted "in a plethora of inadequacies that threaten our society," according to a report by the agency's Science Board." Given the FDA's admission of its shortcomings and it's failure in the Heparin case, the confidence placed in it by the Supreme Court of the United States is misplaced.